#United States #San Antonio #Lumicell #LumiSystem #SABCS

Lumicell's Innovative Contributions at SABCS 2024

Lumicell, Inc., a pioneering company focused on fluorescence-guided imaging technologies for cancer surgeries, showcased significant findings at the 2024 San Antonio Breast Cancer Symposium (SABCS), held from December 10 to 13. The company presented compelling poster sessions that emphasized patient satisfaction and outcomes associated with the use of their LumiSystem™ technology during lumpectomy procedures.

Positive Patient Feedback

Howard Hechler, CEO of Lumicell, expressed excitement over the positive feedback received from patients regarding their experiences with LumiSystem. Many patients reported satisfactory cosmetic outcomes after having suspicious tissue excised with the assistance of fluorescence-guided imaging. This technology not only assists in removing cancerous tissues effectively but also may contribute to lower instances of patients requiring additional surgeries.

A significant 70.6% of participants in patient satisfaction surveys preferred to avoid further surgery in favor of satisfactory cosmetic results, highlighting the value of implementing LumiSystem in lumpectomy processes.

Details from Poster Presentations

During the symposium, Lumicell presented various studies:

1. Does additional margin excision during LumiSystem fluorescence-guided lumpectomy surgery affect patient breast satisfaction?
Author: Barbara Smith, M.D.
Key Findings: After 6-12 months, the mean satisfaction score for patients using LumiSystem was 79.8, compared to 78.2 for the control group. No significant differences were noted (p = 0.359).

2. LumiSystem-guided lumpectomy enables informed customization of radiation therapy.
Author: Simona Shaitelman, M.D.
Key Findings: Among 357 patients, those undergoing LumiSystem-guided surgeries showed that some could either reduce their radiation therapy volume or avoid it altogether while benefiting from the removal of unexpected residual tumors.

These positive outcomes demonstrate Lumicell's commitment to improving the surgical experience and patient outcomes in breast cancer treatment. In addition to enhancing the efficacy of tumor removal, LumiSystem presents an opportunity to customize follow-up treatments based on real-time imaging data.

The Future of Radiation Therapy Customization

The findings presented by Lumicell also indicate a paradigm shift in how radiation therapy might be administered. Specifically, the utilization of LumiSystem can lead to the possibility of revising traditional protocols based on clearer visualization of the surgical site, representing a step forward in personalized medicine.

Such advancements encourage healthcare providers to consider LumiSystem as an integral part of the lumpectomy procedure, aiming for optimization not just in terms of cancer removal but also concerning patients' overall health outcomes and satisfaction.

About Lumicell, Inc.

Lumicell is dedicated to enhancing oncological surgery through advanced imaging technology. Their leading products, the optical imaging agent LUMISIGHT™ (pegulicianine) and the Lumicell Direct Visualization System (DVS), are formulated to illuminate the surgical site to help detect remaining cancerous tissues effectively. Moving forward, Lumicell continues to explore the utility of its imaging technology across various solid tumor indications, proving that their innovations can potentially transform cancer treatment protocols positively.

For more information about LumiSystem and ongoing developments, visit Lumicell's official website.

Conclusion

The findings from the 2024 San Antonio Breast Cancer Symposium not only reinforce Lumicell's role as an innovator in cancer surgery but also underscore a shared vision of improving patient outcomes. The integration of advanced imaging technologies like LumiSystem could change the landscape of breast cancer treatment, creating more personalized and effective avenues for patient care.